Cross-border genetic testing by Barton, David
ORAL PRESENTATION Open Access
Cross-border genetic testing
David Barton
From 5th European Conference on Rare Diseases (ECRD 2010)
Krakow, Poland. 13-15 May 2010
As genetic testing (GT) is now available for many rare
disorders, no GT laboratory can be expert enough to
provide every test. Samples are therefore sent between
laboratories for testing, often across borders. Such
cross-border testing raises some questions:
The 2003 OECD survey of 827 molecular GT labora-
tories in 18 countries found that 64% of laboratories
had received samples from abroad. This percentage is
likely to have increased in the intervening years, but no
data are available.
Samples are usually sent abroad for specialist testing,
but factors such as patents on genes and the centralisa-
tion of testing by private pathology companies also con-
tribute to the traffic.
The main issue identified in the OECD report was the
wide range of quality frameworks operating in different
countries, leading to uncertainty about the quality of
GT results obtained when samples are sent across bor-
ders. EuroGentest, with Orphanet, has established a
quality assurance database of 1500 laboratories provid-
ing genetic tests in Europe. The database uniquely
includes validated informati o no na c c r e d i t a t i o ns t a t u s
and EQA participation for each laboratory and each
test. For the public, this database facilitates an informed
choice of laboratories; for genetic services, it allows the
selection of partners for referral of tests based on their
commitment to quality; for the laboratories, it valorises
their efforts and investment in quality assurance.
W h i l et h eI nV i t r oD i a g n o s t i c( I V D )D i r e c t i v er e g u -
lates the quality of diagnostic devices in the EU, most
GT is exempt from the Directive as tests are manufac-
tured and used in the same institution. EuroGentest has
proposed that this exemption from CE-marking should
be retained in the revised IVD Directive but it should be
restricted to laboratories accredited to ISO 15189 or
equivalent. This would protect the availability of rare
disease testing, but ensure that it was carried out in
laboratories with a robust quality system.
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